EDAP Share Price

Open 3.15 Change Price %
High 3.21 1 Day -0.02 -0.63
Low 3.07 1 Week 0.12 3.96
Close 3.15 1 Month 0.05 1.61
Volume 34042 1 Year -1.28 -28.89
52 Week High 4.80
52 Week Low 2.43
EDAP Important Levels
Resistance 2 3.28
Resistance 1 3.23
Pivot 3.14
Support 1 3.07
Support 2 3.02
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ETRM 0.07 0.00%
AAPL 113.86 1.55%
AAPL 113.86 1.55%
More..
NASDAQ USA Top Gainers Stocks
HTCO 11.00 62.96%
LOCM 0.09 50.00%
OPXA 1.21 40.70%
QKLS 0.18 38.46%
ZAZA 0.08 33.33%
MOSY 0.46 31.43%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PPHM 0.40 25.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
BGMD 0.05 -37.50%
More..

EDAP TMS S.A. (NASDAQ: EDAP)

EDAP Technical Analysis 1.5
As on 9th Dec 2016 EDAP Share Price closed @ 3.15 and we RECOMMEND Sell for LONG-TERM with Stoploss of 3.33 & Buy for SHORT-TERM with Stoploss of 2.90 we also expect STOCK to react on Following IMPORTANT LEVELS.
EDAP Target for December
1st Target up-side 3.58
2nd Target up-side 3.97
3rd Target up-side 4.35
1st Target down-side 2.48
2nd Target down-side 2.09
3rd Target down-side 1.71
EDAP Other Details
Segment EQ
Market Capital 24019672.00
Sector Healthcare
Industry Medical Appliances & Equipment
Offical website http://www.edap-tms.com
EDAP Address
EDAP
Parc d'activit
4, rue du Dauphine
Vaulx-en-Velin, 69120
France
Phone: 33 4 72 15 31 50
Fax: 33 4 72 15 31 51
Interactive Technical Analysis Chart EDAP TMS S.A. ( EDAP NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on EDAP TMS S.A.
EDAP Business Profile
Edap Tms SA (EDAP) is engaged in developing and marketing the Ablatherm device, an advanced choice for high intensity focused ultrasound (HIFU) treatment of localized prostate cancer. The Company operates two divisions: HIFU and urology devices and services (UDS) (including lithotripsy activities). Through these two divisions, the Company develops, produces and markets minimally invasive medical devices, mainly for urological diseases HIFU treatment is shown to be a minimally invasive treatment option for localized prostate cancer with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option. It is also used for patients who failed a radiotherapy treatment. In addition, the Company is developing HIFU technology for the treatment of certain other types of tumors.